Medical devices

Regulator to reexamine cardiac stent prices as manufacturers threaten to withdraw from India

Benefits of price cap still not available to all as some hospitals have raised the prices of treatment packages involving stents.

With the National Pharmaceutical Pricing Authority or NPPA set to revise the cardiac stent prices caps in January 2018, multinational companies are already signalling that they might withdraw existing stents from the market.

In February 2017, the NPPA had capped the prices of the stents by invoking Para 19 of the Drug Price Control Order, which allows the authority to regulate the prices of drugs and medical devices that are not under the National List of Essential Medicines under extraordinary circumstances in public interest.

Cardiac stents are small scaffolds that are inserted into blood vessels during procedures called angioplasties to unblock the vessels, restore normal blood flow and thereby prevent heart attacks.

Before stent prices were capped, they were sold at exorbitant prices. The most commonly used type of stent called drug-eluting stent could cost as much as Rs 2.5 lakh. The NPPA fixed the ceiling price for this variety of stent at Rs 29,600. However, the NPPA price order is time bound. “The order was valid for one year,” said Bhupendra Singh, chairman of NPPA. “We have invited suggestions from all stakeholders and by January we will have meetings to decide on the capping.”

Amid speculation the price cap will not continue after the first year, Singh clarified that the government is considering extending the order capping stent prices for a longer period of time.

In the past few months, several companies have asked the authority to reconsider the pricing of some stents, which they claim are technologically more advanced than the older stents, and therefore should be priced higher.

In November, the NPPA invited suggestions from Indian drug manufacturers and importers. “The companies will have to come up with clinical data to explain if there is any new development that differentiates these stents,” said Singh.

The NPPA will be advised by a committee constituted by the government on the matter of revising the ceiling rates. “The decision of NPPA will be final,” said Singh. “The committee will have a advisory role only,”

However, the authority is under enormous pressure from industry to remove any sort of price cap. United States Trade Representative and Ambassador Robert B Lighthizer asserted in a letter to the Indian government that US stent manufacturers have been discouraged from introducing the latest technology in the Indian market.

Patients vs hospitals vs stent manufacturers

The aim of capping the prices of cardiac stents was to make angioplasties affordable to all patients. “Yes, there is no doubt that the number of people undergoing angioplasties, for whom cost was a factor, has gone up,” said Dr Vijay Surase, cardiologist at Jupiter Hospital in Thane.

At the same time, benefits of the price cap have not been passed on to many patients because several hospitals have found ways around the price cap. “Some hospitals have raised the packages of the total angioplasty procedures,” said Surase.

Although the NPPA can take action against hospitals for overcharging patients for stents, it cannot regulate other charges levied on the patients. Since February, the NPPA has registered about 40 complaints for overcharging of stents.

Medical device manufacturing companies said that hospitals making super profits off stents resulted in the NPPA’s stringent crackdown. “Globally, the prices had reduced over the last few years but hospitals in India refused to reduce the maximum retail price even when the cost to the company had drastically reduced,” said a person working in the medical device industry.

Medical device manufacturers and doctors claim the price cap will limit the introduction of the latest technology cardiac stents in India. “First there was balloon angioplasty which had high restenosis rates, following which came the cardiac stents and latest are the drug eluting stents to further reduce the risk of restenosis,” said a senior executive from an international medical device company. Restenosis is to the narrowing of a blood vessel, that has already been treated for blockage.

“Now, the latest stents have innovations with respect to the designs which gives benefits that only clinicians can appreciate.”

A company representative working for an international medical device company in western India said that if the price are not corrected to suit the industry, more companies will apply to withdraw their stent products.

But, activists working for price control in the medical device industry feel that only claims of stent innovation are not enough. Malini Aisola, convenor of the All India Drugs Action Network who monitors the medical device industry closely said that a doctor’s perception about the efficacy of the cardiac stent is not enough. “Companies need to conduct research and prove the benefits in terms of treatment outcome to claim superiority,” she said.

In fact, NPPA’s chairman Singh has asked companies to come up with clinical data to prove the difference (in efficacy) between the stents.

Surase said that amid the discussion about stent pricing, he is witnessing a drop in patients who come to Indian hospitals from outside India. “I have seen a drop in patients coming from Middle East as people perceive that quality stents are not available in India.”

We welcome your comments at
Sponsored Content BY 

Some of the most significant innovations in automotive history made their debut in this iconic automobile

The latest version features India's first BS VI norms-compliant engine and a host of 'intelligent' features.

The S-Class, also known as Sonderklasse or special class, represents Mercedes Benz’ top-of-the-line sedan line up. Over the decades, this line of luxury vehicles has brought significant automotive technologies to the mainstream, with several firsts to its credit and has often been called the best car in the world. It’s in the S-Class that the first electronic ESP and ABS anti-lock braking system made their debut in the 20th century.

Twenty first-century driver assistance technologies which predict driver-behaviour and the vehicle’s course in order to take preventive safety measures are also now a staple of the S-Class. In the latest 2018 S-Class, the S 350 d, a 360-degree network of cameras, radars and other sensors communicate with each other for an ‘intelligent’ driving experience.

The new S-Class systems are built on Mercedes Benz’s cutting-edge radar-based driving assistance features, and also make use of map and navigation data to calculate driving behaviour. In cities and on other crowded roads, the Active Distance Assist DISTRONIC helps maintain the distance between car and the vehicle in front during speeds of up to 210 kmph. In the same speed range, Active Steering Assist helps the driver stay in the centre of the lane on stretches of straight road and on slight bends. Blind Spot Assist, meanwhile, makes up for human limitations by indicating vehicles present in the blind spot during a lane change. The new S-Class also communicates with other cars equipped with the Car-to-X communication system about dicey road conditions and low visibility due to fog, rain, accidents etc. en route.

The new S-Class can even automatically engage the emergency system when the driver is unable to raise an alarm. Active Emergency Stop Assist brings the car to a stop if it detects sustained periods of inactivity from the driver when Active Steering Assist is switched on. If the driver doesn’t respond to repeated visual and audible prompts, it automatically activates the emergency call system and unlocks the car to provide access to first responders.

The new Mercedes-Benz S 350 d in India features another notable innovation – the country’s first BS VI norms-compliant car engine, in accordance with government regulations to control vehicular pollution. Debuting two years before the BS VI deadline of 2020, the S 350 d engine also remains compatible with the current BS IV fuels.

The S 350 d is an intelligent car made in India, for Indian roads - in the Mercedes Benz S-Class tradition. See the video below to know what drives the S-Class series by Mercedes Benz.

To know more about the 2018 S-Class, click here.


This article was produced by the Scroll marketing team on behalf of Mercedes Benz and not by the Scroll editorial team.